Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12630-010-9350-0 | DOI Listing |
J Child Neurol
November 2002
Division of Neurology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Six children developed severe daily migraine-type headaches during cancer treatment. In addition to chemotherapy drugs, all received daily doses of ondansetron, a 5-hydroxytryptamine type 3 receptor antagonist. 5-Hydroxytryptamine is considered to play a central role in migraine pathogenesis, and ondansetron may have caused headaches by producing 5-hydroxytryptamine dysfunction in the brain.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!